BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS. 2007;21:1405-1414. [PMID: 17589186 DOI: 10.1097/qad.0b013e3281ac229b] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Hachiya A, Marchand B, Kirby KA, Michailidis E, Tu X, Palczewski K, Ong YT, Li Z, Griffin DT, Schuckmann MM, Tanuma J, Oka S, Singh K, Kodama EN, Sarafianos SG. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors. J Biol Chem 2012;287:29988-99. [PMID: 22761416 DOI: 10.1074/jbc.M112.351551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, Kumarasamy N, Hosseinipour MC, Jarocki B, Mellors JW, Collier AC; ACTG A5273 Study Group. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 2016;3:e247-58. [PMID: 27240787 DOI: 10.1016/S2352-3018(16)30011-X] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
3 Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG. Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology 2013;10:65. [PMID: 23800377 DOI: 10.1186/1742-4690-10-65] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
4 Scarth BJ, White KL, Chen JM, Lansdon EB, Swaminathan S, Miller MD, Götte M. Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother 2011;55:2662-9. [PMID: 21402840 DOI: 10.1128/AAC.01738-10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23:1127-34. [PMID: 19417582 DOI: 10.1097/QAD.0b013e32832ac34e] [Cited by in Crossref: 212] [Cited by in F6Publishing: 133] [Article Influence: 17.7] [Reference Citation Analysis]
6 Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF. Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. Eur J Med Chem 2011;46:3832-44. [PMID: 21700368 DOI: 10.1016/j.ejmech.2011.05.051] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
7 Tu X, Das K, Han Q, Bauman JD, Clark AD Jr, Hou X, Frenkel YV, Gaffney BL, Jones RA, Boyer PL, Hughes SH, Sarafianos SG, Arnold E. Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol 2010;17:1202-9. [PMID: 20852643 DOI: 10.1038/nsmb.1908] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 8.1] [Reference Citation Analysis]
8 Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008;47:14020-7. [PMID: 19067547 DOI: 10.1021/bi8014778] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
9 Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009;385:693-713. [PMID: 19022262 DOI: 10.1016/j.jmb.2008.10.071] [Cited by in Crossref: 319] [Cited by in F6Publishing: 255] [Article Influence: 24.5] [Reference Citation Analysis]
10 Schneider A, Corona A, Spöring I, Jordan M, Buchholz B, Maccioni E, Di Santo R, Bodem J, Tramontano E, Wöhrl BM. Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors. Nucleic Acids Res 2016;44:2310-22. [PMID: 26850643 DOI: 10.1093/nar/gkw060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
11 Das K, Bandwar RP, White KL, Feng JY, Sarafianos SG, Tuske S, Tu X, Clark AD Jr, Boyer PL, Hou X, Gaffney BL, Jones RA, Miller MD, Hughes SH, Arnold E. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 2009;284:35092-100. [PMID: 19812032 DOI: 10.1074/jbc.M109.022525] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
12 Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Martinez-Cajas JL, Brenner BG, Wainberg MA. A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 2011;6:e20208. [PMID: 21655292 DOI: 10.1371/journal.pone.0020208] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
13 Avidor B, Turner D, Mor Z, Chalom S, Riesenberg K, Shahar E, Pollack S, Elbirt D, Sthoeger Z, Maayan S, Olshtain-Pops K, Averbuch D, Chowers M, Istomin V, Anis E, Mendelson E, Ram D, Levy I, Grossman Z. Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. PLoS One 2013;8:e57789. [PMID: 23469241 DOI: 10.1371/journal.pone.0057789] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
14 Wainberg MA. The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo) 2012;2012:238278. [PMID: 24278679 DOI: 10.6064/2012/238278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Trivedi V, Von Lindern J, Montes-Walters M, Rojo DR, Shell EJ, Parkin N, O'Brien WA, Ferguson MR. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility. AIDS Res Hum Retroviruses 2008;24:1291-300. [PMID: 18844463 DOI: 10.1089/aid.2007.0244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Harrigan PR, Sheen CW, Gill VS, Wynhoven B, Hudson E, Lima VD, Lecocq P, Aguirre R, Poon AF, Sluis-Cremer N. Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. AIDS 2008;22:2501-8. [PMID: 19005273 DOI: 10.1097/QAD.0b013e328318f16c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
17 Ntemgwa ML, Toni Td, Brenner BG, Oliveira M, Asahchop EL, Moisi D, Wainberg MA. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother 2009;53:708-15. [PMID: 19064892 DOI: 10.1128/AAC.01109-08] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
18 Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. J Antimicrob Chemother 2010;65:307-15. [PMID: 20008905 DOI: 10.1093/jac/dkp419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG. Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses 2010;2:606-38. [PMID: 20376302 DOI: 10.3390/v2020606] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
20 Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol 2015;10:1773-82. [PMID: 26517190 DOI: 10.2217/fmb.15.106] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
21 Roy V, Obikhod A, Zhang HW, Coats SJ, Herman BD, Sluis-Cremer N, Agrofoglio LA, Schinazi RF. Synthesis and anti-HIV evaluation of 3'-triazolo nucleosides. Nucleosides Nucleotides Nucleic Acids 2011;30:264-70. [PMID: 21623540 DOI: 10.1080/15257770.2011.580291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Meteer JD, Schinazi RF, Mellors JW, Sluis-Cremer N. Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. Antiviral Res 2014;101:62-7. [PMID: 24211331 DOI: 10.1016/j.antiviral.2013.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
23 Chunduri H, Rimland D, Nurpeisov V, Crumpacker CS, Sharma PL. A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus. Virol J 2011;8:33. [PMID: 21255423 DOI: 10.1186/1743-422X-8-33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 2009;3:583-94. [PMID: 20190870 DOI: 10.2217/hiv.09.40] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
25 Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 2010;285:12101-8. [PMID: 20164190 DOI: 10.1074/jbc.M109.096529] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
26 Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012;72:e1-25. [PMID: 22686620 DOI: 10.2165/11633630-000000000-00000] [Cited by in Crossref: 190] [Cited by in F6Publishing: 167] [Article Influence: 21.1] [Reference Citation Analysis]
27 McCluskey SM, Siedner MJ, Marconi VC. Management of Virologic Failure and HIV Drug Resistance. Infect Dis Clin North Am 2019;33:707-42. [PMID: 31255384 DOI: 10.1016/j.idc.2019.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
28 Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother 2012;56:5000-8. [PMID: 22733071 DOI: 10.1128/AAC.00591-12] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
29 Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009;53:3611-9. [PMID: 19470514 DOI: 10.1128/AAC.00154-09] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
30 Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF. Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. Antivir Ther 2010;15:185-92. [PMID: 20386073 DOI: 10.3851/IMP1514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
31 Garforth SJ, Parniak MA, Prasad VR. Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptase. PLoS One 2008;3:e2074. [PMID: 18446195 DOI: 10.1371/journal.pone.0002074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
32 Cortez KJ, Maldarelli F. Clinical management of HIV drug resistance. Viruses. 2011;3:347-378. [PMID: 21994737 DOI: 10.3390/v3040347] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]